Houston’s role in the booming weight-loss drug industry is beginning to take shape.
New state filings this month revealed the first major steps in Eli Lilly and Company’s planned $6.5 billion pharmaceutical manufacturing campus in northeast Houston, where the drugmaker expects to produce medicines including its experimental GLP-1 pill, orforglipron.
The five projects outlined in filings with the Texas Department of Licensing and Regulation account for nearly 700,000 square feet of construction and an estimated $378 million in construction. Together, they offer the clearest look yet at what Eli Lilly plans to build first at 12550 Timber Forest Drive in Generation Park…